Variability in treatment patterns for the cancer type.Total cost of care linked with the cancer type.Prevalence of the cancer type in the payer’s population.The top 5 considerations when deciding which cancer types to include in the OCP were:
Decrease costs linked with anticancer drugs.The top 5 reasons for using OCPs included the following: Of the 43 respondents, 18 (42%) said they were currently using OCPs, and 16 (37%) were considering it. Forty-three responded 35% were medical directors and 65% were pharmacy directors. The research was conducted by Xcenda, part of AmerisourceBergen.Īn electronic payer survey containing multiple-choice, open-ended, and Likert scale–rating questions was sent in November 2020 to Xcenda’s Managed Care Network, the company’s research panel of more than 160 managed care professionals. This research examined how OCPs initiated by payers affected access to oncology treatments, as payers seek ways to manage high-cost oncology care while ensuring value-based care. In 2016, they were used by 58% of oncology practices, which was 42% more than in 2014. The use of OCPs, which first appeared about a decade ago, has grown in recent years. A poster presented at the Academy of Managed Care Pharmacy 2021 meeting, April 12-16, 2021, examined how payers in the United States are using oncology clinical pathways (OCPs) to understand what drives their development and uptake and to delineate what barriers prevent further OCP adoption.
0 kommentar(er)
